AxoGen Appoints Michael Dale as Chief Executive-February 2024-www.financetom.com

AxoGen Appoints Michael Dale as Chief Executive

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

AxoGen Appoints Michael Dale as Chief Executive

Aug 8, 2024 9:49 AM

12:21 PM EDT, 08/08/2024 (MT Newswires) -- AxoGen ( AXGN ) said Thursday that it appointed Michael Dale as chief executive, effective Friday.

Dale succeeds Karen Zaderej who will remain with AxoGen ( AXGN ) in an advisory role for nine months, according to the company.

Dale's past executive leadership roles span both public and private medical device companies, the firm said.

Board member Paul Thomas will become the new chairman of the board, effective Friday, AxoGen ( AXGN ) added.

Price: 10.46, Change: +2.54, Percent Change: +32.01

Previous page： National Bank Reviews Pivotree's Q4 -- Trims Target to $3, Reiterates Outperform Next page： MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

National Bank Reviews Pivotree's Q4 -- Trims Target to $3, Reiterates Outperform

Mar 27, 2024

03:01 PM EDT, 03/27/2024 (MT Newswires) -- Pivotree ( PVTRF ) reported its Q4 results with soft top-line performance care of macro-related project delays and the continued transition away from legacy solutions. The company was able to offset that softness with cost optimizations and still delivered a positive adj. EBITDA. The sequential growth in the leading indicator PS bookings suggests...

MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products

Mar 27, 2024

03:06 PM EDT, 03/27/2024 (MT Newswires) -- MiMedx Group ( MDXG ) said Wednesday the US Food and Drug Administration affirmed that Axiofill, a human-derived particulate wound dressing, does not meet the regulatory requirements as a Human Cell, Tissue or Cellular or Tissue-based Product under Section 361 of the Public Health Service Act. The FDA issued its decision in a...

Market Chatter: Artisan Partners Asset Management Increases Stake in Barry Callebaut

Mar 27, 2024

02:59 PM EDT, 03/27/2024 (MT Newswires) -- Artisan Partners Asset Management ( APAM ) increased its shareholding in Barry Callebaut to 5.5% from 3% in February, Bloomberg News reported, citing SIX Exchange. Artisan Partners is the second largest stakeholder in the Swiss-Belgian chocolate maker behind Jacobs Holding, which owns a 30% stake, according to the report. Neither Artisan Partners nor...

Merck's Winrevair Poised for Strong Launch Following US FDA Approval, UBS Says

Mar 27, 2024

03:09 PM EDT, 03/27/2024 (MT Newswires) -- Merck's ( MRK ) Winrevair is poised for a strong launch after the US Food and Drug Administration approved the medicine with a clean label and no significant warning or risk evaluation and mitigation strategy program, UBS said in a note emailed Wednesday. Noting that concerns of potential gastrointestinal bleeding as a result...